LONDON, Sept 4 (Reuters) - Britain's Destiny Pharma , which is developing drugs to target antibiotic-resistant bacterial infections, has raised 15.3 million pounds ($19.8 million) by listing shares on London's AIM market.
from Reuters: New Issues News http://ift.tt/2eVASZM
Tidak ada komentar:
Posting Komentar